PolyPid Ltd. (PYPD): Price and Financial Metrics

PolyPid Ltd. (PYPD): $0.53

-0.03 (-4.64%)

POWR Rating

Component Grades













PYPD Stock Price Chart Interactive Chart >

Price chart for PYPD

PYPD Price/Volume Stats

Current price $0.53 52-week high $6.90
Prev. close $0.56 52-week low $0.50
Day low $0.50 Volume 34,932
Day high $0.58 Avg. volume 434,296
50-day MA $0.75 Dividend yield N/A
200-day MA $2.27 Market Cap 10.44M

PolyPid Ltd. (PYPD) Company Bio

PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The company was founded by Noam Emanuel in 2008 and is headquartered in Petach Tikva, Israel.

PYPD Latest News Stream

Event/Time News Detail
Loading, please wait...

PYPD Latest Social Stream

Loading social stream, please wait...

View Full PYPD Social Stream

Latest PYPD News From Around the Web

Below are the latest news stories about POLYPID LTD that investors may wish to consider to help them evaluate PYPD as an investment opportunity.

PolyPid to Present at the Barclays Global Healthcare Conference

PETACH TIKVA, Israel, March 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 14-16, 2023. Barclays Global Investor Conference: Presentation Date: Tuesday, March 14, 2023Presentation Time:4:35 PM Eastern Time Investors interested in meeting with PolyPid during th

Yahoo | March 7, 2023

PolyPid Ltd. (NASDAQ:PYPD) Q4 2022 Earnings Call Transcript

PolyPid Ltd. (NASDAQ:PYPD) Q4 2022 Earnings Call Transcript February 8, 2023 Operator: Greetings, and welcome to the PolyPid Fourth Quarter and Full Year 2022 Conference Call. . As a reminder, this call is recorded. And I would now like to introduce your host for today’s conference, Brian Ritchie from LifeSci Advisors. Mr. Ritchie, you may […]

Yahoo | February 9, 2023

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Following Positive Communication with the FDA, Regulatory Pathway Clarified for D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections Company Expects to Resume Patient Recruitment in Q2 2023 into Ongoing SHIELD II Trial, which will be Enriched with Approximately 550 Additional Patients to Complete Clinical Testing for Potential NDA Top-line Results from SHIELD II Trial Anticipated mid-2024 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 08, 2023 (

Yahoo | February 8, 2023

PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023

PETACH TIKVA, Israel, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full year 2022 financial results and operational

Investors Polypid | January 31, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday!

William White on InvestorPlace | January 25, 2023

Read More 'PYPD' Stories Here

PYPD Price Returns

1-mo -27.40%
3-mo -29.33%
6-mo -54.11%
1-year -90.52%
3-year N/A
5-year N/A
YTD -24.01%
2022 -87.85%
2021 -42.02%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8065 seconds.